*Applications will be reviewed on a rolling-basis.
Two research opportunities are available in the Office of Translational Sciences/ Office of Clinical Pharmacology, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
This project will evaluate the landscape of available information and scientific considerations around intranasal, intramuscular, or intravenous routes of opioid antagonist development addressing prescription opioid overdose reversal, and illicit highly potent opioid overdose reversal.
Under the guidance of a mentor, the participant will perform background research pertaining to approved and unapproved opioid-antagonists for overdose reversal, including literature search regarding potency of illicit opioids such as synthetic fentanyl’s in preclinical and clinical setting. Overall, the participant will develop understanding of specific knowledge gaps that exist in the development of opioid overdose reversal involving highly potent illicit opioids.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment can be full-time or part-time, depending on the participant’s availability, at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
The qualified candidate should be currently pursuing or have received a bachelor’s, master’s or doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity (FDA-CDER-2020-0563) in your email.